Studied in models involving nicotinamide N-methyltransferase signaling, methylation-linked metabolism, and metabolic pathway regulation
10.1016/0968-0004(93)90019-J
Saxenda was one of the earliest GLP-1 medications specifically indicated for weight loss, and although newer agents now offer greater potency, Saxenda remains a valuable option for patients who prefer daily dosing, respond well to its metabolic effects, or have insurance coverage that favors this formulation
Loras C, Mendes AC, Peixe L, Novais , Als JI
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health
They each failed to make the cut as top recommendations for our readers, but we cover them here to be as thorough in our depiction of the landscape as possible